Needham analyst Gil Blum has maintained their neutral stance on FOLD stock, giving a Hold rating on February 6.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gil Blum’s rating is based on the current valuation of Amicus’s stock, which he perceives as fully priced at existing levels. Despite the company’s positive performance, with notable product sales growth in 2024 and promising projections for 2025, the stock does not appear undervalued or poised for significant price appreciation in the near term.
Additionally, while Amicus has outlined robust sales growth plans for its products and is expanding its market reach globally, the anticipated growth rate is expected to decelerate slightly. These factors collectively influence the decision to assign a Hold rating, suggesting that investors might consider maintaining their current positions without aggressively buying more shares.
According to TipRanks, Blum is an analyst with an average return of -9.0% and a 32.64% success rate. Blum covers the Healthcare sector, focusing on stocks such as Cartesian Therapeutics, Sarepta Therapeutics, and Autolus Therapeutics.
In another report released on February 6, Morgan Stanley also maintained a Hold rating on the stock with a $12.00 price target.